Neil Alan Cross

This study shows that combining hypoxia-activated prodrugs with chemotherapy disrupts metabolic resistance mechanisms in osteosarcoma by targeting ferroptosis, glycolysis, and survival pathways.

This study evaluates the combination of epigenetic modifiers with an anti-DR5 agonistic mAb to enhance anti-cancer efficacy in osteosarcoma cell lines.

This study evaluates ferroptosis inducers and Nrf2 inhibitors as radiosensitizers in 2D and 3D breast cancer models, finding no significant enhancement of radiosensitivity.